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The optimization of nanoparticles (NP) for drug delivery, in particular to target the BBB, imposes to verify their
hemocompatibility both for toxicological and efficiency of targeting perspectives. Indeed the large surface they are able to expose
to the biological environment promotes their interaction with various biochemicals, in particular proteins which can after
adsorption elicit the activation of biological cascades either responsible from NP clearance or/and harmful body reaction
(inflammatory / coagulation).
In the frame of the European Integrated Project : “Nanobiopharmaceutics”, we have the opportunity to compare the
hemoreactivity of about 145 different NP samples differing in core and surface chemistry and classified according to their
expected difference in hydrophobicity based on the nature of their core materials. According to this classification, PLGA
nanoparticles, polyglycidol-polyethyethylene oxide nanoparticles, polyglycidol thyolated or polyacrylamide nanogels, and
polyelectrolyte complexes either based on polyamidoamine or poly(N,N-dimethylamino-2-ethylmethacrylate) have been evaluated
within a concentration ranging from 0.3 to 1000 µg/mL. These in vitro tests have been realized for screening purpose adopting
normal human bloods and according to Iso 10993.
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The main possible hemoreactions of the blood components 
Conclusions
• Blood components : sensitive medium to the presence of NP’s ;  crucial parameter to take into consideration in the design of NP’s for 
the future, in particular for BBB applications
• Some of the biological parameters (platelets, Intrinsic pathway of coagulation and C3a) are typically more reactive
• Useful correlations between NP’s properties and blood reactivity can already be extracted from these data (additional information 
should be implemented to better understand these differences in hemoreactivity). A KEY result of Nanobiopharmaceutics regarding 
Nanotoxicological aspects.
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